The RSI Oscillator for AMRN moved out of oversold territory on October 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 27 of the 35 cases the stock moved higher. This puts the odds of a move higher at 77%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AMRN as a result. In 61 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for AMRN just turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 42 of 55 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
AMRN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMRN entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.607) is normal, around the industry mean (-2.729). P/E Ratio (-10.621) is within average values for comparable stocks, (20.997). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for NAGE turned positive on October 27, 2026. Looking at past instances where NAGE's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NAGE's RSI Indicator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 73 cases where NAGE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on NAGE as a result. In 72 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAGE advanced for three days, in 188 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
NAGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for NAGE entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.435) is normal, around the industry mean (1.736). P/E Ratio (12.700) is within average values for comparable stocks, (6.461). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.056) among similar stocks. P/S Ratio (1.976) is also within normal values, averaging (4.925).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. NAGE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AMRN | NAGE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 45 | |
PRICE GROWTH RATING 1..100 | 75 | 85 | |
P/E GROWTH RATING 1..100 | 32 | 93 | |
SEASONALITY SCORE 1..100 | 50 | 9 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NAGE's Valuation (62) in the Chemicals Specialty industry is in the same range as AMRN (66) in the Pharmaceuticals Other industry. This means that NAGE’s stock grew similarly to AMRN’s over the last 12 months.
NAGE's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that NAGE’s stock grew similarly to AMRN’s over the last 12 months.
NAGE's SMR Rating (45) in the Chemicals Specialty industry is somewhat better than the same rating for AMRN (92) in the Pharmaceuticals Other industry. This means that NAGE’s stock grew somewhat faster than AMRN’s over the last 12 months.
AMRN's Price Growth Rating (75) in the Pharmaceuticals Other industry is in the same range as NAGE (85) in the Chemicals Specialty industry. This means that AMRN’s stock grew similarly to NAGE’s over the last 12 months.
AMRN's P/E Growth Rating (32) in the Pharmaceuticals Other industry is somewhat better than the same rating for NAGE (93) in the Chemicals Specialty industry. This means that AMRN’s stock grew somewhat faster than NAGE’s over the last 12 months.
| AMRN | NAGE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 85% |
| Advances ODDS (%) | 3 days ago 73% | 1 day ago 75% |
| Declines ODDS (%) | 13 days ago 85% | 15 days ago 83% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 81% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while NAGE’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 4 TA indicator(s) are bullish while NAGE’s TA Score has 6 bullish TA indicator(s).
AMRN (@Pharmaceuticals: Major) experienced а +10.73% price change this week, while NAGE (@Food: Major Diversified) price change was +2.83% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.41%. For the same industry, the average monthly price growth was -5.87%, and the average quarterly price growth was +2.51%.
The average weekly price growth across all stocks in the @Food: Major Diversified industry was -1.58%. For the same industry, the average monthly price growth was -7.75%, and the average quarterly price growth was -21.11%.
NAGE is expected to report earnings on Nov 04, 2026.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Food: Major Diversified (-1.58% weekly)Companies in this industry usually make a diverse range of agricultural and/or processed food. Some prominent names in this segment are Mondelez International, which makes chocolates, biscuits, cookies etc. The Kraft Heinz Company specializes in ketchups, sauces, fruit drink pouches and many more. General Mills, Inc. sells flour and cereal. Kellogg is famous for its snacks and breakfast cereal. And so on down the line. As more and more consumers are looking for healthier options in food in recent years, several legacy food companies have responded by revamping brands to include organic and no-added-sugar versions, and/or acquiring healthy food firms, and even streamlining operations.
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | +6.65% | ||
| CNTB - AMRN | 55% Loosely correlated | +0.33% | ||
| HRTX - AMRN | 44% Loosely correlated | +2.45% | ||
| MGNX - AMRN | 44% Loosely correlated | +1.23% | ||
| ALXO - AMRN | 43% Loosely correlated | +7.27% | ||
| ARWR - AMRN | 40% Loosely correlated | +2.00% | ||
More | ||||
A.I.dvisor indicates that over the last year, NAGE has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NAGE jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To NAGE | 1D Price Change % | ||
|---|---|---|---|---|
| NAGE | 100% | +1.60% | ||
| AXON - NAGE | 43% Loosely correlated | -0.63% | ||
| USNA - NAGE | 39% Loosely correlated | +3.91% | ||
| TRDA - NAGE | 38% Loosely correlated | +9.75% | ||
| AMRN - NAGE | 35% Loosely correlated | +6.65% | ||
| CYTK - NAGE | 35% Loosely correlated | -0.39% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LOUP | 81.85 | 1.28 | +1.59% |
| Innovator Deepwater Frontier Tech ETF (LOUP) | |||
| ONEQ | 104.68 | 0.33 | +0.32% |
| Fidelity Nasdaq Composite Index ETF (ONEQ) | |||
| IFEB | 31.36 | 0.07 | +0.22% |
| Innovator International Developed Power Buffer ETF February (IFEB) | |||
| EBI | 65.35 | N/A | N/A |
| The RBB Fund Trust Longview Advantage ETF | |||
| BNDD | 97.86 | -0.42 | -0.43% |
| Quadratic Deflation ETF (BNDD) | |||